Salary list of big boss of pharmaceutical enterprises: some people increased by 318%, others reduced by 1.5 million

What's the "salary" of the drug tycoons in 2016? E-medicine managers exclusively sorted out the remuneration of the leaders of 61 listed pharmaceutical companies, some of them still ranked first, some of them were aggressive, while others ended up with zero remuneration Portal: big boss of pharmaceutical enterprises in 2015 salary ranking: average 1.12 million, Chen Qiyu, Yan Kaijing, Li Xiulin occupy the top three According to the statistics of Hewitt, the salary of pharmaceutical industry in 2016 increased by 7.7% on average Among them, the salary growth of local pharmaceutical enterprises was significantly higher than that of foreign pharmaceutical enterprises, 1.4% higher In addition, the average growth rate of the overall salary proportion (excluding promotion) of Chinese local pharmaceutical enterprises in 2016 is 8.4%, which is expected to decrease slightly to 8.3% by 2017 So, what's the salary of these drug giants in 2016? As there are still many pharmaceutical companies that have not disclosed their annual reports, according to 61 A-share pharmaceutical listed companies that have already disclosed their annual reports, e pharmaceutical managers have made statistics on the annual salary of the big boss of pharmaceutical companies (including the chairman, President, general manager, etc.): the average annual salary of the 61 pharmaceutical companies that have been disclosed is 1.4379 million yuan, an increase of 16.8% compared with 2015 Chen Qiyu, chairman of Fosun Pharmaceutical, still tops the list In 2016, the pre tax salary reached 8.9 million yuan, a year-on-year increase of 1 million yuan Another noteworthy is Zhao Tao, chairman of step pharmaceutical, who just became the richest man in China's pharmaceutical industry After landing in the capital market last year, Zhao Tao's annual pre tax salary was 6.69 million yuan And Huabei pharmaceutical, which has changed its chairman for three years and three years, is at the end Only three months after taking office, Guo zhouke, chairman of Huabei pharmaceutical, resigned for personal reasons As a result, his pre tax salary was 0 in the annual report In terms of salary increase, Gong Daoyi, chairman of Guangji Pharmaceutical Co., Ltd., made 600000 yuan in 2016, with a year-on-year increase of 318.7%, becoming the biggest increase in pharmaceutical companies The reason for this is that according to the remuneration plan for directors and senior managers in 2016 previously issued by Guangji pharmaceutical, the annual salary of the chairman of the board is 600000 yuan, 60% of which is paid monthly as the basic annual salary In addition, the annual performance salary is the embodiment of the annual operating efficiency, which is linked to the operating results, work performance and contribution of directors and senior executives, and is assessed on the basis of 40% of the annual salary standard In 2016, Guangji pharmaceutical realized revenue of 715 million yuan, a year-on-year increase of 27.55% The net profit attributable to the shareholders of the listed company increased by 577.96% to 142 million yuan, which is the main reason why Gong Daoyi's salary increased so much Zhang Lijun, chairman of Harbin Pharmaceutical Co., Ltd., saw the biggest decrease in salary, with a year-on-year decrease of 72.1% In the annual report, this was explained Harbin Pharmaceutical Co., Ltd said that since Zhang Lijun was the head of municipal state-owned enterprises appointed by the Organization Department of Harbin Municipal Committee of the Communist Party of China, according to the relevant regulations on the salary assessment and management of the head of municipal state-owned enterprises, before the disclosure of the company's annual report, its total annual salary was still in the approval of the superior departments For this reason, Zhang Lijun's daily wages and salaries during the reporting period are not all the total pre tax remuneration   Different from Gong Daoyi's and Zhang Lijun's small base numbers, Chen Qiyu, chairman of Fosun Pharmaceutical Co., Ltd., has increased the most money in the past year His annual salary has increased from 7.9 million yuan in 2015 to 8.9 million yuan, an increase of 1 million yuan The reason for the increase is that Fosun has achieved the target set in 2015 Yao Xiaoqing of HongRi Pharmaceutical Co., Ltd has the largest decrease in the specific salary In 2015, its annual salary dropped from 5.058 million yuan to 3.4927 million yuan, making 1513100 yuan less than that in 2015 Yao's salary decline was not caused by the decline in performance, but by the adjustment of the salary of the executives of HongRi pharmaceutical industry Because the salary of the executives of HongRi pharmaceutical industry increased a lot in the past years, it was widely questioned by the media.